Stay updated on Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The update appears to be limited to minor layout and formatting adjustments on the study page; core details like inclusion criteria, outcomes, and participating sites remain unchanged.
    Difference
    0.4%
    Check dated 2025-11-03T13:44:04.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    38 days ago
    Change Detected
    Summary
    Added a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.
    Difference
    4%
    Check dated 2025-10-06T04:14:51.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Updated to Revision: v3.1.0 with expanded contact details; old Revision: v3.0.2 removed.
    Difference
    0.1%
    Check dated 2025-09-28T23:34:25.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Updated from v3.0.1 to v3.0.2; removed the 'Back to Top' element. No other substantive changes to core content, pricing, stock, or time-slot availability.
    Difference
    0.2%
    Check dated 2025-09-14T09:52:43.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.
    Difference
    0.2%
    Check dated 2025-09-07T07:52:37.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    The web page has updated its facility name and location details, including specific drug information and available locations in Beijing and Changchun, while removing several previous location references and cancer-related terms.
    Difference
    2%
    Check dated 2025-08-31T01:00:23.000Z thumbnail image

Stay in the know with updates to Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.